trending Market Intelligence /marketintelligence/en/news-insights/trending/8dyb35a-b3rrmhohl_ewbq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Histogenics plans offering of common stock, warrants

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Histogenics plans offering of common stock, warrants

Histogenics Corp. plans to offer its common shares and accompanying warrants to buy common shares in an underwritten public offering.

All of the securities being issued in the offering will be sold by the clinical-stage company.

The Waltham, Mass.-based company plans to use the net proceeds from the offering to submit the biologics license application and prepare for marketing of NeoCart, a tissue implant, following approval by the U.S. Food and Drug Administration.

NeoCart is a tissue implant in a phase 3 study to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

In addition, the net proceeds will be used for general corporate purposes.

Canaccord Genuity LLC and BTIG LLC are acting as the joint book-running managers for the offering.